(2,5-Dioxooxolan-3-yl) 2,2,2-trifluoroacetate | 83477-75-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2,5-Dioxooxolan-3-yl) 2,2,2-trifluoroacetate
• CAS: 83477-75-2
• 化学式: C₆H₃F₃O₅
• 分子量: 212.082
• InChiKey: VDOMJGLWVPHKFA-UHFFFAOYSA-N

物化性质

• 沸点：
  276.4±40.0 °C(Predicted)
• 密度：
  1.62±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  69.7
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  甲醇 、 (2,5-Dioxooxolan-3-yl) 2,2,2-trifluoroacetate 生成 2-羟基琥珀酸甲酯
  参考文献：
  名称：

  Use of enantio-, chemo- and regioselectivity of acylase I. Resolution of polycarboxylic acid esters

  摘要：

  Acylase I was used to catalyze the enantioselective butanolysis of trimethyl 2-[(carboxymethyl)oxy]succinate (E=30) and N-carboxymethylaspartate (E=9) exclusively at the most sterically hindered of the three ester group's (the position alpha to the asymmetric centre). Gram-scale resolution allowed the preparation of the less reactive trimethyl (S)-2-[(carboxymethyl)oxy]succinate (96% e.e.), that of the (R)-butyldimethyl regioisomer (78% e.e.) at 55% conversion and finally the preparation of the corresponding trisodium carboxylate by saponification. Acylase I was shown to transform (+/-)-methyl N-acetylmethionine and (+/-)-valine to the corresponding (S)-amino acids through ester hydrolysis-N-acetyl transfer sequence with absolute chemo- and enantioselectivity. Butanolysis of methyl N-acetylmethionine stopped in the formation of the butyl ester (E=12), the valine derivative being totally unreactive. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(01)00362-7
• 作为产物：
  描述：

  苹果酸 、 三氟乙酸酐 反应 2.0h， 生成 (2,5-Dioxooxolan-3-yl) 2,2,2-trifluoroacetate
  参考文献：
  名称：

  Enantioselective syntheses of 3-substituted 4-(alkoxycarbonyl)-2-azetidinones from malic acid

  摘要：

  DOI：

  10.1021/jo00146a020

文献信息

• POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20180297994A1

  公开（公告）日：2018-10-18

  The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.

  本申请涉及肌动蛋白M2受体的阳性变构调节剂，特别是新型的7-取代的1-芳基萘啶-3-羧酰胺，以及其制备方法，单独或组合使用于治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病和/或肾脏疾病。
• [EN] ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS
  申请人：GLAXO GROUP LTD

  公开号：WO2013052568A1

  公开（公告）日：2013-04-11

  The present Invention relates to cephalosporin antibacterial compounds of Formula (!): corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods for bacterial infections, especially those caused by gram-negative bacteria.

  本发明涉及头孢菌素抗菌化合物的公式（I）：以及相应的药学上可接受的盐、相应的药物组合物、化合物制备和治疗细菌感染的方法，特别是由革兰氏阴性细菌引起的感染。
• [EN] USE OF PHENOLIC COMPOUNDS FROM OLEA EUROPAEA<br/>[FR] UTILISATION DE COMPOSÉS PHÉNOLIQUES ISSUS D'OLEA EUROPAEA
  申请人：MCCORD DARLENE E

  公开号：WO2019033010A1

  公开（公告）日：2019-02-14

  A series of phenolic compounds with similar inhibitory COX-1 and COX-2 properties as oleocanthal and oleuropein is described here. The phenolic compounds disclosed here were also found to be MAO and LSD-1 inhibitors. Also provided are methods of using these phenolic compounds in various formulations and compositions including food additives, pharmaceuticals, cosmetics, and animal repellants.

  本文描述了一系列具有类似于欧利可坦和欧洛普林的抑制COX-1和COX-2性质的酚类化合物。这些在此披露的酚类化合物也被发现是MAO和LSD-1的抑制剂。还提供了使用这些酚类化合物在各种配方和组合中的方法，包括食品添加剂、药品、化妆品和动物驱避剂。
• HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE
  申请人：Machinaga Nobuo

  公开号：US20090324581A1

  公开（公告）日：2009-12-31

  To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. The invention provides a compound represented by general formula (I) (wherein A is a single bond, —O—, or —CH 2 —; R 1 represents a hydrogen atom or a C 1 -C 6 alkyl group, and V represents any one group selected from among the following groups (1) to (3): (1) -G 1 -, (2) -G 2 -N(R 2 )-G 3 -, and (3) a group represented by formula 2, wherein each of Z 1 and Z 2 represents a hydrogen atom or a C 1 -C 6 alkyl group, Z 3 represents a hydrogen or the like, Q represents —CH 2 —O— or the like, and Y represents a group represented by formula 3, a salt thereof, or a solvate thereof.

  提供一种新型化合物，具有S1P受体激动活性，表现出优异的免疫抑制效果，产生较少的不良副作用，并可口服。本发明提供一种由通式（I）表示的化合物（其中A是单键，-O-或-CH2-；R1表示氢原子或C1-C6烷基基团，V表示从以下组（1）至（3）中选择的任一组：（1）-G1-，（2）-G2-N（R2）-G3-，以及（3）由式2表示的组，其中Z1和Z2分别表示氢原子或C1-C6烷基基团，Z3表示氢或类似物，Q表示-CH2-O-或类似物，Y表示由式3表示的基团，其盐或溶剂化物。
• ANTIBACTERIAL COMPOUNDS
  申请人：GLAXO GROUP LIMITED

  公开号：US20140249126A1

  公开（公告）日：2014-09-04

  The present invention relates to cephalosporin antibacterial compounds of Formula (I): or corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods for bacterial infections, especially those caused by gram-negative bacteria.

  本发明涉及式（I）的头孢菌素抗菌化合物：或其相应的药学上可接受的盐，相应的制药组合物，化合物制备和治疗细菌感染的方法，特别是由革兰氏阴性菌引起的感染。